期刊文献+

ER、Her-2、Ki-67在原发灶和复发灶中表达差异观察

Differential expression of ER,HER-2 and Ki-67 in primary and recurrent lesions
下载PDF
导出
摘要 目的研究雌激素受体(ER)、人表皮生长因子受体-2(Her-2)、细胞核增殖抗原(Ki-67)在原发灶和复发灶中的表达差异。方法回顾性选择2017年3月至2021年3月蚌埠医学院第二附属医院收治的82例局部复发乳腺癌患者作为研究对象。使用免疫组织化学法和荧光原位杂交技术(FISH)检测患者原发灶和复发灶中ER、Her-2、Ki-67表达。观察ER、Her-2、Ki-67在原发灶、复发灶中的表达。结果乳腺癌患者原发灶中ER、Her-2、阳性表达率分别为54.88%、24.39%,复发灶中ER、Her-2阳性表达率分别为51.22%、19.51%,两种病灶中ER、Her-2阳性表达率比较,差异均无统计学意义(P>0.05);原发灶和复发灶中Ki-67高表达率分别为52.44%、71.95%,复发灶中Ki-67高表达比率较原发灶高,差异有统计学意义(P<0.05)。原发灶和复发灶中ER、Her-2、Ki-67表达一致率分别为80.49%、86.59%、76.83%。患者年龄、组织学分级与ER、Her-2、Ki-67表达差异无明显相关性(P>0.05);临床分期为Ⅲ或Ⅳ期的患者ER表达不一致率较高(P<0.05)。结论局部复发乳腺癌患者的原发灶和复发灶中ER、Her-2、Ki-67的表达存在较高的一致性,但仍含有部分患者的表达存在一定差异,临床有必要同时检测患者的原发灶和复发灶,可能有助于临床治疗方案的选择。 Objective To study the expression differences of estrogen receptor(ER),human epidermal growth factor receptor-2(HER-2)and nuclear proliferation antigen(Ki-67)in primary and recurrent lesions.Methods A total of 82 patients with locally recurrent breast cancer admitted in the Second Affiliated Hospital of Bengbu Medical College from March 2017 to March 2021 were retrospectively selected and divided into primary group(n=37)and recurrent group(n=45)according to the type of lesion.The expressions of Er,HER-2 and Ki-67 were detected by immunohistochemistry and fluorescence in situ hybridization(FISH).The expressions of ER,HER-2 and Ki-67 in primary and recurrent lesions were observed.Results The positive expression rates of ER,HER-2 and ER-2 were 54.88%and 24.39%in the primary tumor,and 51.22%and 19.51%in the recurrence tumor,respectively.There was no significant difference in the positive expression rates of ER and HER-2 between the two lesions,the difference were no statistically significant(P>0.05).The high expression rate of Ki-67 in primary and recurrent foci was 52.44%and 71.95%,respectively.The high expression rate of Ki-67 in recurrent foci was higher,the difference was statistically significant(P<0.05).The consistent expression rates of ER,HER-2 and Ki-67 were 80.49%,86.59%and 76.83%in the primary group and recurrence group,respectively.There was no significant correlation between age and histological grade and the expression of ER,HER-2 and Ki-67(P>0.05).Patients with clinical stageⅢorⅣhad a higher rate of inconsistent ER expression(P<0.05).Conclusion Compared with primary tumors,the positive rate of Ki-67 expression in breast cancer patients was higher than that in primary lesions,but there was no difference in ER and Her-2 between primary and recurrent foci.This suggests that Ki-67 has higher value in the evaluation of recurrent foci.
作者 安赵 王晓丹 刘飞 马靖靖 金功圣 AN Zhao;WANG Xiao-dan;LIU Fei(Surgical Oncology,the Second Affiliated Hospital of Bengbu Medical College,Bengbu Anhui 233000,China)
出处 《临床和实验医学杂志》 2022年第7期758-761,共4页 Journal of Clinical and Experimental Medicine
基金 安徽省教育厅关于2017年高校自然科学研究项目(编号:KJ2017A245)。
关键词 乳腺癌 雌激素受体 人表皮生长因子受体-2 KI-67蛋白 预后 Breast cancer Estrogen receptor Human epidermal growth factor receptor-2 Ki-67 protein Prognosis
  • 相关文献

参考文献12

二级参考文献59

  • 1<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:164
  • 2Watters AD,Going JJ,Cooke GT,et al.Chromosome 17 aneusomy is associated with poor prognostic factors in invesive breast carcinoma.Breast Cancer Res Treat,2003,77:109-114.
  • 3Bilous M,Morey A,Armes J,et al.Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.Pathology,2006,38:120-124.
  • 4Goldhirsch A,Glick JH,Gelber RD,et al.Meeting highlights:international expert consensus on the primary therapy of early breast cancer 2005.Annals Oncol,2005,16:1569-1583.
  • 5The Center For Devices and Radiological Health (CDRH) of the Food and Drug Administration.A document of evaluation about the PathVysionTM HER-2 DNA Probe Kit of Vysis,INC.for detecting amplification of the HER-2/neu gene via fluorescence in situ hybridization (FISH) in formalin-fixed,paraffin-embedded human breast cancer tissue specimens.[2001-12-31].http://www.fda.gov/cdrh/pmapage.html.
  • 6Shak S.Overview of the trastuzumab (Hereeptin) anti-HER2monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer.Herceptin Multinational Investigator Study Group.Semin Oncol,1999,26(4 Suppl 12):71-77.
  • 7Hammock L,Lewis M,Philips,C,et al.Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.Hum Pathol,2003,34:1043-1047.
  • 8北京市发展和改革委员会.关于公布荧光原位杂交基因检测(FISH)等新增医疗服务价格项目的通知.京发改[2006]1376号.http://www.bjpc.gov.cn/tztg/200608/t129145.btm.
  • 9Hicks DG,Tubbs RR.Assessment of the Her2 status in breast cancer by fluorescence in situ hybridization:a technical review with interpretive guidelines.Hum Pathol,2005,36:250-261.
  • 10Wang S,Hossein Saboorian H,Frenkel EP,et al.Aneusomy 17 in breast cancer:its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status.Mod Pathol,2002,15:137-145.

共引文献1393

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部